Mumbai, Maharashtra Mar 23, 2020 (Issuewire.com) - KRISHGEN BIOSYSTEMS brings Coronavirus Testing in different formats for quick screening and confirmatory testing.
KRISHGEN, today announced that, as on March 23, 2020, it entered into a Transfer Technology License and Commercialization Agreement with Genuine Biosystem Pvt Ltd, Chennai, India for the Coronavirus testing kits. Krishgen will in turn have worldwide distribution and commercialization rights to this product line for use in clinical markets.
The technology developed and validated by KRISHGEN and transferred for manufacturing involves the real time PCR kits (developed as per CDC Atlanta, USA guidelines), the only product worldwide for quality screening of patient using antigen ELISA format and the rapid antibody testing format.
SARS-CoV-2 (Covid-19) Real Time (RT-qPCR) detection kit
Genlisa™ SARS-CoV-2 (Covid-19) Antigen ELISA kit
Genlisa™ Anti-SARS-CoV-2 (Covid-19) IgG-IgM Rapid Test
All these products have been CE marked by the manufacturer for use in the clinical market. Its manufacturing partner has been granted testing license from CDSCO, India for pass-through validation of these products to market.
"Krishgen is uniquely positioned to provide life sciences products to researcher and pharmaceutical companies worldwide. We continue to deliver on our promise to bring the best technologies and products.”
About KRISHGEN BIOSYSTEMS
Krishgen Biosystems, headquartered in Mumbai, India is a bio-supplier focused on offering solutions for immunoassays, cell cultures and toxicology to researchers. Krishgen offers products across the research and drug discovery segment including GENBULK™, GENLISA™, KRISHZYME™, KRISHGEN™, KRIBIOLISA™, KRISHPLEX™, TITANIUM™.
For more information, please visit: www.krishgen.com
Forward Looking Statements
This press release contains forward-looking statements about our business, research, development and commercialization efforts, including statements regarding the development and commercialization of future products and our ability to bring solutions to the research and biopharmaceutical segment. These forward-looking statements are based upon information that is currently available to us and our current expectations, speak only as of the date hereof, and are subject to numerous risks and uncertainties, including risks associated with successful research, development and planned commercialization of our technologies. We expressly disclaim any obligation, except as required by law, or undertaking to update or revise any such forward-looking statements.
CONTACTS:
KRISHGEN BIOSYSTEMS
Kalpesh Jain
Chief Operating Officer
91-22-49198700
info@krishgen.com
Media Contact
KRISHGEN BIOSYSTEMS krishgen.mumbai@gmail.com 912249198700 Unit Nos 318 319 Shah and NaharOff Dr E Moses RoadWorli http://www.krishgen.com
